

# Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 31890 Insp GMP 31890/383321-0022

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

## Part 1

Issued following an inspection in accordance with :  
Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ALMAC SCIENCES LIMITED

Site address : ALMAC SCIENCES LIMITED, ALMAC HOUSE, 20 SEAGOE INDUSTRIAL ESTATE, CRAIGAVON, BT63 5QD,  
UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 07/05/2025 , it is considered that it complies with

- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- 
- (1) *Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
  - (2) *These requirements fulfil the GMP recommendations of WHO.*

## Part 2

### Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [2000017443] URIDINE TRIACETATE
- [2000019268] REZAFUNGIN ACETATE
- [2000018682] AMIFAMPRIDINE PHOSPHATE
- [3000017276] SELEXIPAG
- [1000018046] ACTIVE SUBSTANCES FOR CLINICAL TRIALS

### 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

URIDINE TRIACETATE

- 3.1 Manufacture of Active Substance by Chemical Synthesis
  - 3.1.2 Manufacture Of Crude Active Substance
  - 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)  
crystallisation
- 3.5 General Finishing Steps
  - 3.5.2 Primary Packaging
  - 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
  - 3.6.1 Physical / Chemical testing

REZAFUNGIN ACETATE

- 3.1 Manufacture of Active Substance by Chemical Synthesis
  - 3.1.1 Manufacture Of Active Substance Intermediates
  - 3.1.2 Manufacture Of Crude Active Substance
  - 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)  
purification step using Prep Chromatography
  - 3.1.4 Other  
Freeze Drying
- 3.5 General Finishing Steps
  - 3.5.1 Physical Processing Steps  
Blending
  - 3.5.2 Primary Packaging
  - 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
  - 3.6.1 Physical / Chemical testing

AMIFAMPRIDINE PHOSPHATE

- 3.1 Manufacture of Active Substance by Chemical Synthesis
  - 3.1.1 Manufacture Of Active Substance Intermediates
  - 3.1.2 Manufacture Of Crude Active Substance
  - 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)  
crystallisation
- 3.5 General Finishing Steps

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

#### SELEXIPAG

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)  
crystallisation

3.5 General Finishing Steps

3.5.1 Physical Processing Steps  
micronisation

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

#### ACTIVE SUBSTANCES FOR CLINICAL TRIALS

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)  
crystallisation, distillation, chromatography or similar alternatives

3.5 General Finishing Steps

3.5.1 Physical Processing Steps  
micronisation

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.5.4 Other

Blending & Milling

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

11/02/2026	Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential
------------	---

MHRA-GMDP

MHRA

MHRA